Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Zheyong Huang,1,* Yanan Song,1,* Zhiqing Pang,2 Bo Zhang,3 Hongbo Yang,1 Hongtao Shi,1 Jing Chen,1 Hui Gong,1,4 Juying Qian,1 Junbo Ge1,4 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 2School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Deliver...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Huang Z, Song Y, Pang Z, Zhang B, Yang H, Shi H, Chen J, Gong H, Qian J, Ge J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/ba30ecd1723a49958d7f141709deb878
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ba30ecd1723a49958d7f141709deb878
record_format dspace
spelling oai:doaj.org-article:ba30ecd1723a49958d7f141709deb8782021-12-02T07:22:52ZTargeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles1178-2013https://doaj.org/article/ba30ecd1723a49958d7f141709deb8782017-04-01T00:00:00Zhttps://www.dovepress.com/targeted-delivery-of-thymosin-beta-4-to-the-injured-myocardium-using-c-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Zheyong Huang,1,* Yanan Song,1,* Zhiqing Pang,2 Bo Zhang,3 Hongbo Yang,1 Hongtao Shi,1 Jing Chen,1 Hui Gong,1,4 Juying Qian,1 Junbo Ge1,4 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 2School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 3Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 4Institute of Biomedical Science, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Purpose: Thymosin beta 4 (Tβ4) has multiple beneficial facets for myocardial injury, but its efficiency is limited by the low local concentration within the infarct. Here, we established a Tβ4 delivery system for cardiac repair based on the interaction between the abundant fibrin in the infarct zone and the fibrin-targeting moiety clot-binding peptide cysteine–arginine–glutamic acid–lysine–alanine (CREKA). Methods and results: CREKA and Tβ4 were conjugated to nanoparticles (CNP–Tβ4). In vitro binding test revealed that CNP–Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP–Tβ4). Based on the validation of fibrin expression in the early stage of ischemia injury, CNP–Tβ4 was intravenously administered to mice with acute myocardial ischemia–reperfusion injury. CNP–Tβ4 revealed a stronger fibrin-targeting ability than the NP–Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin. Subsequently, treatment with CNP–Tβ4 resulted in a better therapeutic effect. Conclusion: CRKEA modification favored Tβ4 accumulation and retention in the infarcted region, leading to augmented functional benefits. Fibrin-targeting delivery system represents a generalizable platform technology for regenerative medicine. Keywords: thymosin beta 4, fibrin, CREKA, targeting delivery, ischemia reperfusion, cardiovascularHuang ZSong YPang ZZhang BYang HShi HChen JGong HQian JGe JDove Medical PressarticleThymosin beta 4FibrinCREKATargeting deliveryIschemia reperfusionCardiovascularMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 3023-3036 (2017)
institution DOAJ
collection DOAJ
language EN
topic Thymosin beta 4
Fibrin
CREKA
Targeting delivery
Ischemia reperfusion
Cardiovascular
Medicine (General)
R5-920
spellingShingle Thymosin beta 4
Fibrin
CREKA
Targeting delivery
Ischemia reperfusion
Cardiovascular
Medicine (General)
R5-920
Huang Z
Song Y
Pang Z
Zhang B
Yang H
Shi H
Chen J
Gong H
Qian J
Ge J
Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
description Zheyong Huang,1,* Yanan Song,1,* Zhiqing Pang,2 Bo Zhang,3 Hongbo Yang,1 Hongtao Shi,1 Jing Chen,1 Hui Gong,1,4 Juying Qian,1 Junbo Ge1,4 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 2School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 3Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 4Institute of Biomedical Science, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Purpose: Thymosin beta 4 (Tβ4) has multiple beneficial facets for myocardial injury, but its efficiency is limited by the low local concentration within the infarct. Here, we established a Tβ4 delivery system for cardiac repair based on the interaction between the abundant fibrin in the infarct zone and the fibrin-targeting moiety clot-binding peptide cysteine–arginine–glutamic acid–lysine–alanine (CREKA). Methods and results: CREKA and Tβ4 were conjugated to nanoparticles (CNP–Tβ4). In vitro binding test revealed that CNP–Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP–Tβ4). Based on the validation of fibrin expression in the early stage of ischemia injury, CNP–Tβ4 was intravenously administered to mice with acute myocardial ischemia–reperfusion injury. CNP–Tβ4 revealed a stronger fibrin-targeting ability than the NP–Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin. Subsequently, treatment with CNP–Tβ4 resulted in a better therapeutic effect. Conclusion: CRKEA modification favored Tβ4 accumulation and retention in the infarcted region, leading to augmented functional benefits. Fibrin-targeting delivery system represents a generalizable platform technology for regenerative medicine. Keywords: thymosin beta 4, fibrin, CREKA, targeting delivery, ischemia reperfusion, cardiovascular
format article
author Huang Z
Song Y
Pang Z
Zhang B
Yang H
Shi H
Chen J
Gong H
Qian J
Ge J
author_facet Huang Z
Song Y
Pang Z
Zhang B
Yang H
Shi H
Chen J
Gong H
Qian J
Ge J
author_sort Huang Z
title Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
title_short Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
title_full Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
title_fullStr Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
title_full_unstemmed Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
title_sort targeted delivery of thymosin beta 4 to the injured myocardium using creka-conjugated nanoparticles
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/ba30ecd1723a49958d7f141709deb878
work_keys_str_mv AT huangz targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT songy targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT pangz targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT zhangb targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT yangh targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT shih targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT chenj targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT gongh targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT qianj targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
AT gej targeteddeliveryofthymosinbeta4totheinjuredmyocardiumusingcrekaconjugatednanoparticles
_version_ 1718399475493371904